Yichen Wang1, Haiyan Sun1, Aijun Yu1, Tao Zhu1, Xi Chen2. 1. Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Science, China; Department of Gynecological Surgery, Cancer Hospital of the University of Chinese Academy of Sciences, China; Department of Gynecological Surgery, Zhejiang Cancer Hospital, Hangzhou, China. 2. Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Science, China; Department of Gynecological Surgery, Cancer Hospital of the University of Chinese Academy of Sciences, China; Department of Gynecological Surgery, Zhejiang Cancer Hospital, Hangzhou, China. Electronic address: xiang10301030@163.com.
Abstract
BACKGROUND: The impact of chemotherapy on disease-specific survival in patients with borderline ovarian tumors (BOTs) has not been studied previously. METHODS: Patients with BOTs were identified from The Surveillance, Epidemiology, and End Results (SEER) database. Associations of chemotherapy and other risk factors with disease-specific survival were analyzed using Cox proportion hazards regression models. RESULTS: A total of 6065 patients diagnosed during 1988-2000 were selected. The mean age at diagnosis was 48.0 ± 16.5 with a median follow-up time of 190.0 ± 72.5 months. The majority of BOTs were at stage I (86.7%) and treated with surgery (99.3%). Chemotherapy and radiotherapy were given to 343 patients (5.7%) and 33 (0.5%) patients, respectively. A total of 296 patients (4.9%) died from this disease. Both univariate and multivariate survival analysis showed that chemotherapy, older age, bilateral tumor, advanced stage, non-surgery and radiotherapy were associated with worse disease-specific survival. The comprised effect of chemotherapy remained after patients were stratified by age, histology and stage. CONCLUSIONS: Chemotherapy is associated with worse disease-specific survival in patients with BOTs. Tumor laterality, age, stage and other treatments are also prognostic factors for this disease.
BACKGROUND: The impact of chemotherapy on disease-specific survival in patients with borderline ovarian tumors (BOTs) has not been studied previously. METHODS:Patients with BOTs were identified from The Surveillance, Epidemiology, and End Results (SEER) database. Associations of chemotherapy and other risk factors with disease-specific survival were analyzed using Cox proportion hazards regression models. RESULTS: A total of 6065 patients diagnosed during 1988-2000 were selected. The mean age at diagnosis was 48.0 ± 16.5 with a median follow-up time of 190.0 ± 72.5 months. The majority of BOTs were at stage I (86.7%) and treated with surgery (99.3%). Chemotherapy and radiotherapy were given to 343 patients (5.7%) and 33 (0.5%) patients, respectively. A total of 296 patients (4.9%) died from this disease. Both univariate and multivariate survival analysis showed that chemotherapy, older age, bilateral tumor, advanced stage, non-surgery and radiotherapy were associated with worse disease-specific survival. The comprised effect of chemotherapy remained after patients were stratified by age, histology and stage. CONCLUSIONS: Chemotherapy is associated with worse disease-specific survival in patients with BOTs. Tumor laterality, age, stage and other treatments are also prognostic factors for this disease.